Notably, in prostate cancer, several clinical trials have investigated the effects of IGF-1R inhibitors in combination with other drugs, such as mitoxantrone (NCT00683475) or docetaxel [27]. The gene discussed is IGF1R; the disease is prostate carcinoma.